한글목차

신경교종 치료 동향 및 전망

세계 신경교종 치료 시장은 2024년부터 2030년까지 연평균 4.1%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 다형성교모세포종 발생률 증가, 연구 개발 활동 증가, 전 세계 수술 건수 증가입니다. 세계 신경교종 치료 시장의 미래는 병원 및 클리닉, 진단 센터, 의료 연구 센터 시장에서의 기회로 인해 유망한 것으로 보입니다.

• Lucintel은 원발성 종양 치료에 대한 수요가 증가함에 따라 유형별로는 원발성 종양이 예측 기간 동안 계속 큰 부문을 차지할 것으로 예상했습니다.
• 최종사용자 카테고리에서 병원 및 클리닉은 종합적인 서비스를 제공하는 옵션이 점점 더 선호됨에 따라 가장 큰 부문을 차지할 것입니다.
• 지역별로 보면 북미는 건강상태에 대한 인식이 높아진 데다 이 지역 내 주요 기업들의 존재로 인해 예측 기간 동안 가장 큰 지역으로 남을 것으로 보입니다.

신경교종 치료 시장에서의 전략적 성장 기회

신경교종 치료 시장은 연구, 기술 및 치료 접근법의 발전으로 인해 몇 가지 전략적 성장 기회가 있습니다. 이러한 기회를 인식하고 활용하는 것은 환자 예후를 개선하고 시장 기반을 확대하고자 하는 이해관계자들에게 중요합니다. 이 개요에서는 혁신과 영향력이 큰 잠재력이 있는 분야를 중심으로 신경교종 치료 시장의 5가지 주요 성장 기회를 소개하고자 합니다.

• 면역치료 확대 : 면역치료 이니셔티브의 일환으로 체크포인트 억제제 및 CAR-T 세포 치료제의 개발 및 상용화에 투자하는 것은 매우 중요합니다. 교모세포종 치료의 경우, 특히 재발성 또는 악성도가 높은 경우 환자들은 이 치료법의 혜택을 받고 있으며, 추가 연구와 임상시험을 통해 확대되면 병세를 크게 개선할 수 있습니다. 효과적인 면역치료제를 성공적으로 개발하는 기업은 신경교종(교모세포종) 치료의 심각한 미충족 수요를 충족시킴으로써 경쟁 우위를 확보할 수 있습니다.
• 정밀의료의 발전 : 분자 프로파일에 기반한 정밀의료 접근법의 개발로 신경교종 분자 이상에 대한 개별화된 유전자 돌연변이 특이적 표적 치료법을 개발할 수 있습니다. 이 개발은 개인 프로파일링에 대한 접근을 촉진할 것입니다. 유전체 시퀀싱과 바이오마커의 발견이 개선되면, 표적 환자에 대한 자본 투자가 더욱 현실화될 것이며, 이는 프론티어 과학 연구와 기술에 투자할 수 있는 기회가 될 것입니다.
• 첨단 영상 기술의 성장 : 첨단 영상 진단 기술을 기반으로 한 더 나은 진단 도구에 대한 투자는 필수적입니다. 기능적 MRI 및 PET 스캔과 같은 최신 영상 진단 방법은 종양의 특징과 치료에 대한 반응에 대한 인사이트를 제공합니다. 영상 진단 능력의 향상은 모니터링 및 수술 절차의 개선으로 이어집니다. 따라서 영상 기술 관련 기업들은 신경교종 치료의 현재 결함을 해결할 수 있는 혁신적인 솔루션을 제공할 수 있는 매력적인 기회를 가지고 있습니다.
• 약물전달 시스템의 혁신 : 혈액뇌장벽 침투와 치료 효과를 개선하기 위한 새로운 약물전달 시스템 개발은 매우 중요합니다. 대류 촉진 전달 및 나노기술과 같은 혁신적인 약물전달 기술을 통해 치료제를 종양 부위에 전달할 수 있습니다. 이러한 발전은 약물의 침투와 효능에 대한 우려를 해소하고 더 나은 치료 결과를 가져올 수 있는 큰 잠재력을 제공합니다. 이는 기업들이 신경교종 시장에서 상용화될 관련 개발에 특화함으로써 경쟁 우위를 확보할 수 있는 가능성을 보여줍니다.
• 신흥 시장 진출 : 고급 신경교종 치료에 대한 수요가 증가하고 있는 신흥 시장에서 입지를 확대하는 것은 필수적입니다. 인도, 중국 등의 시장은 의료 인프라가 잘 갖추어져 있고 환자 수가 지속적으로 증가하고 있어 큰 잠재력을 가지고 있습니다. 이들 지역에서의 입지는 새로운 현금 흐름을 창출하고 미충족 수요를 충족시킬 수 있는 잠재력을 가지고 있습니다. 기존 시장 진입과 성장을 촉진하기 위해 현지 이해관계자들과 파트너십을 형성해야 합니다. 또한, 각 국가별 요구사항에 맞는 비즈니스 모델을 개발할 수 있습니다.

전략적인 성장 기회에는 면역치료 확대, 정밀의료 추진, 첨단 영상 기술 투자, 약물전달 시스템 혁신, 신흥국 시장 공략 등이 포함됩니다. 이러한 기회를 활용하면 혁신을 촉진하는 동시에 환자의 복지를 개선하고 신경교종 치료 산업의 이해관계자들 사이에서 시장 지위를 향상시킬 수 있습니다.

신경교종 치료 시장의 촉진요인 및 과제

신경교종 치료 시장은 성장을 촉진하고 도전을 제시하는 몇 가지 기술적, 경제적, 규제적 요인에 의해 형성되고 있습니다. 시장을 촉진하고 효과적인 전략을 수립하기 위해서는 이러한 촉진요인과 과제를 이해해야 합니다. 주요 촉진요인으로는 연구 및 기술 발전, 치료 프로토콜의 진화, 맞춤형 의료에 대한 수요 증가 등이 있으며, 높은 개발 비용, 규제 장벽 및 시장 경쟁을 포함한 도전 과제가 있습니다.

신경교종 치료 시장을 주도하는 요인은 다음과 같습니다.

1. 기술 발전 : 유전체학, 이미징 양식, 약물전달 시스템의 기술 발전은 신경교종 치료 시장의 성장을 촉진하는 주요 요인으로 작용하고 있습니다. 첨단 영상 진단 기술 및 정밀의료와 같은 기술 혁신은 보다 정확한 진단과 표적화된 치료를 가능하게 합니다. 혁신적인 약물전달 시스템은 혈액뇌장벽(BBB)을 우회하여 치료 효과를 높일 수 있다는 보고도 있습니다. 이러한 개발은 환자들에게 선택의 폭을 넓히고 치료 결과를 개선하는 데 도움이 될 수 있습니다.

2. 연구개발에 대한 투자 확대 : 연구개발에 대한 투자 확대는 신경교종 치료의 발전을 위해 필수적입니다. 임상시험, 신약 개발 투자, 혁신적인 치료법에 대한 자금 지원은 새로운 치료 옵션으로 이어지는 진전을 촉진하고 있습니다. 제약회사, 정부 기관 및 연구 기관의 이러한 투자는 최첨단 치료법 개발을 촉진하고 과학적 발견이 병원에서 의료 관행으로 전환되는 속도를 높입니다.

3. 맞춤의료에 대한 수요 증가 : 맞춤의료 트렌드는 신경교종 치료 시장의 주요 촉진요인입니다. 유전자 프로파일링 및 분자 프로파일링에 의존함으로써 특정 종양 특성에 대한 특정 표적 치료제를 개발할 수 있습니다. 이러한 접근법은 부작용을 관리하면서 효능을 향상시킬 수 있으며, 환자 중심 치료 및 정밀 종양학에 대한 수요 증가와 일치합니다.

4. 신경교종 유병률 증가 : 신경교종 유병률이 증가함에 따라 효과적인 치료제에 대한 수요가 증가하고 있으며, 이는 시장 확대에 기여하고 있습니다. 고령화 및 기타 환경적 요인으로 인해 발병률이 높아질 수 있습니다. 이러한 치료 수요의 증가는 새로운 치료법과 기술에 대한 혁신과 투자를 촉진할 것입니다.

5. 규제 지원 및 인센티브 : 새로운 신경교종 치료제의 개발은 신속 승인 및 희귀질환 치료제 보조금과 같은 규제 당국의 지원과 인센티브에 의해 촉진됩니다. 규제 기관은 혁신적인 약물의 승인과 상용화를 지원하고 시장 진입을 촉진하며 신경교종 치료의 격차를 해소하는 데 도움을 줄 수 있습니다.

신경교종 치료 시장의 과제는 다음과 같습니다.

6. 높은 개발 비용 : 연구 활동, 임상시험, 규제 준수 등 신경교종 치료제를 개발하는 데 드는 높은 비용은 큰 도전입니다. 이러한 비용은 소규모 기업이 신약을 시장에 출시할 수 있는 능력을 떨어뜨리고, 가격 책정 모델과 환자 접근성에 영향을 미칠 수 있습니다.

7. 규제 장애물 : 새로운 신경교종 치료제의 승인을 받기 위해 규제 요건을 통과하는 것은 복잡하고 시간이 많이 걸립니다. 엄격한 임상시험 규제와 안전성 평가로 인해 어떤 기업도 이 시장에 진입하기 어렵고, 개발 비용을 높이고 시장 진입을 지연시키고 있습니다.

8. 시장 경쟁 : 신경교종 치료제 시장에는 여러 기업이 점유율을 놓고 경쟁하고 있어 시장 경쟁이 치열합니다. 이 분야의 가격 전략과 포지셔닝은 신규 진입 기업뿐만 아니라 기존 제약사로부터도 영향을 받을 수 있습니다. 특히 경쟁에서 우위를 점하기 위해서는 제품 차별화와 임상적 효과를 입증하는 것이 중요한 요소입니다.

기술 발전, 연구 투자 증가, 맞춤형 의료, 유병률 증가, 규제 당국의 지원 등의 요인이 신경교종 치료제 시장에 영향을 미치지만, 높은 개발 비용, 규제 장벽, 치열한 경쟁은 시장 촉진요인이자 도전 과제입니다. 이러한 요인들을 해결하는 것은 진화하는 시장에서 성공하기 위해 신경교종 치료의 발전에 매우 중요한 요소입니다.

목차

제1장 주요 요약

제2장 세계의 신경교종 치료 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 신경교종 치료 시장 동향(2018-2023년)과 예측(2024-2030년)
• 유형별 : 세계의 신경교종 치료 시장
  • 원발성 종양
  • 2차 종양
• 등급별 : 세계의 신경교종 치료 시장
  • 저악성도 신경교종
  • 고악성도 신경교종
  • 재발성 고악성도 신경교종
• 부위별 : 세계의 신경교종 치료 시장
  • 천막상
  • 천막하
• 최종 용도별 : 세계의 신경교종 치료 시장
  • 병원·클리닉
  • 진단 센터
  • 의료 연구 센터
  • 기타

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 : 세계의 신경교종 치료 시장
• 북미의 신경교종 치료 시장
• 유럽의 신경교종 치료 시장
• 아시아태평양의 신경교종 치료 시장
• 기타 지역의 신경교종 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 : 세계의 신경교종 치료 시장 성장 기회
  • 등급별 : 세계의 신경교종 치료 시장 성장 기회
  • 지역별 : 세계의 신경교종 치료 시장 성장 기회
  • 최종 용도별 : 세계의 신경교종 치료 시장 성장 기회
  • 지역별 : 세계의 신경교종 치료 시장 성장 기회
• 세계의 신경교종 치료 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 신경교종 치료 시장 능력 확대
  • 세계의 신경교종 치료 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Thermo Fisher Scientific
• Emcure Pharmaceuticals
• Sigma-Aldrich
• Pfizer
• Taj Pharmaceuticals
• Novartis International
• Teva Pharmaceutical Industries
• GE Healthcare
• Siemens Healthineers
• Philips Healthcare

영문목차

Glioma Treatment Trends and Forecast

The future of the global glioma treatment market looks promising with opportunities in the hospitals & clinics, diagnostic centers, and medical research centers markets. The global glioma treatment market is expected to grow with a CAGR of 4.1% from 2024 to 2030. The major drivers for this market are the increasing incidence of glioblastoma multiforme, growing R&D activities, and the rising number of surgeries performed globally.

• Lucintel forecasts that, within the type category, primary tumors will remain a larger segment over the forecast period due to the escalating need for primary tumor treatment.
• Within the end-use category, hospitals & clinics will remain the largest segment due to people increasingly favoring options that provide comprehensive services.
• In terms of regions, North America will remain the largest region over the forecast period due to elevated awareness regarding less common health conditions and the presence of major players in the region.

Gain valuable insight for your business decisions with our comprehensive 150+ page report

Emerging Trends in the Glioma Treatment Market

This has led to the rapid evolution of the market for glioma treatment due to technological advancements, novel therapies, and an increased understanding of the molecular basis of this disease. These emerging trends transform both diagnosis and treatment approaches for gliomas, giving hope for improved patient outcomes. As scientists and doctors continue to innovate while refining various aspects of care delivery, several factors will determine future trends within the sphere of glioma medical assistance.

• Precision Medicine: Treatments are now being developed based on genetic characteristics at the cellular level-precision medicine is revolutionizing brain tumor therapy by tailoring it to the unique genetic and molecular profiles exhibited by individuals who suffer from this condition. After genome sequencing techniques were improved, biomarkers leading to personalized targeting mechanisms became identifiable, enabling selective targeting of drugs depending on certain mutations present in cancer cells. Consequently, this makes several modalities more efficient while limiting negative effects associated with conventional methods employed previously.
• Immunotherapy: Immunotherapy is proving to be a breakthrough against gliomas, with recently developed checkpoint inhibitors, CAR-T cell therapy approaches, and vaccination-based therapy options. It involves the body's immune system in fighting cancer; that is why it uses means to destroy this type of cell within the human body. These trials have shown promising outcomes, especially for recurrences or high-grade anaplastic astrocytomas. The main departure from typical treatment approaches by immunotherapy denotes that these therapies could result in more efficient and durable response rates, although they still face challenges associated with optimization for gliomas.
• Advanced Imaging Techniques: Glioma diagnosis and treatment are being improved through the integration of functional MRI, PET scans, and intraoperative imaging, among other advanced imaging techniques. They provide a lot of information regarding tumor location, activity levels, and response to intervention, thus enhancing surgical planning and monitoring. This affords better definition between active tumor tissue and the normal brain so that interventions can be performed with true precision. Through visualization of changes occurring during surgery, one can increase the chances for successful operation outcomes while avoiding complications.
• Novel Drug Delivery Systems: Innovative delivery systems for drugs are being developed to enhance glioma treatment effectiveness. By using nanotechnological methods, such as localized drug release and convection-enhanced delivery, these approaches aim to address drug penetration problems through the blood-brain barrier in a bid to improve drug distribution into tumor tissues. To increase therapeutic effects at tumor sites while reducing systemic side effects, mechanisms can employ systems that enable localized delivery of therapeutic agents across the blood-brain barrier, hence minimizing secondary effects on other vital organs. Consequently, they might enhance efficiency during treatment, resulting in better clinical outcomes following glioma therapy procedures.
• Combination Therapies: The use of combination therapies in treating gliomas is on the rise, involving the integration of different therapeutic strategies to achieve synergistic effects. These include combinations of surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapies that have enhanced the treatment of various aspects of these tumors. It seeks a more inclusive approach to therapy, dealing with the potential for overcoming resistance or improving general effectiveness that characterizes this disease process. Different types of gliomas and patient populations are being studied in clinical trials on various combinations.

The glioma care field is being reshaped by emerging trends like precision medicine, immunotherapy, advanced imaging techniques, novel drug delivery systems, and combination therapies. This will yield more efficient personalized treatments that target individual conditions, enhancing patient outcomes and transforming glioma care.

Recent Developments in the Glioma Treatment Market

Over recent years, there have been significant developments in the glioma treatment market, largely driven by advances in technology, the introduction of novel therapies, and changing treatment protocols. Notable developments include new therapeutic agents, surgical technique turnover, and diagnostics improvement. These innovations are shaping future glioma treatment options for patients and healthcare professionals.

• Immunotherapy Advancements: Glioma treatment has recently seen a strong emphasis on immunotherapy, with approaches like checkpoint inhibitors and CAR-T cell therapy showing promise. It is expected that these treatments will improve our immune system response against tumor cells, leading to new hope, especially among patients who suffer from recurrent or high-grade tumors. Results from clinical trials show that these types of drugs can be effective, although challenges remain when trying to optimize them for specific groups suffering from this condition, including managing side effects to assure their efficiency.
• Targeted Therapy Development: Specific genetic mutations and molecular abnormalities linked with gliomas are being considered in developing targeted therapies specifically tailored to them. Key biomarkers and therapeutic targets have been identified as a result of advances in genomic sequencing, leading to the development of drugs that interact with tumor-specific pathways directly. Such treatments aim to improve cure rates and reduce off-target effects, thereby creating a more personalized approach to treating gliomas.
• Advanced Imaging Technologies Integration: Glioma diagnosis and treatment planning are being enhanced by advanced imaging technologies such as functional MRI and PET scans. These techniques help monitor how tumors respond to therapy, improve surgical precision, and reveal key aspects of tumor activity. They are now integrated into real-time visualization during surgery, contributing favorably to better outcomes and fewer complications.
• Drug Delivery Systems Innovations: Overcoming the blood-brain barrier for effective glioma treatment has necessitated exploring novel drug delivery systems. Technological advancements like convection-enhanced delivery (CED) and nanotechnology have been developed to increase drug penetration and efficacy at the tumor site. These innovations can enhance the effectiveness of existing and newly discovered therapeutic agents, thereby improving overall treatment results.
• Emerging Clinical Trials and Research: Ongoing clinical trials and research are currently pushing for progress in glioma therapy, involving investigations into new drug candidates, combinatorial therapies, and innovative treatment modalities. Research efforts focus on finding efficacious therapies, understanding resistance mechanisms, and improving patient selection criteria. These developments have been instrumental in advancing the field while providing new options for glioma patients.

Recent developments in the treatment of glioma, which include immunotherapy advances, targeted therapies, imaging techniques, drug delivery systems, and clinical research, shape the future of care. These breakthroughs provide a new ray of hope for better results and a personalized approach to dealing with gliomas.

Strategic Growth Opportunities for Glioma Treatment Market

The market for glioma treatment offers several strategic growth opportunities resulting from advancements in research, technology, and treatment approaches. Recognition and utilization of these opportunities are important for stakeholders seeking to improve patient outcomes and expand their market base. This overview highlights five major growth opportunities in the glioma treatment market, focusing on areas with substantial potential for innovation and impact.

• Expansion of Immunotherapy: Investing in the development and commercialization of checkpoint inhibitors and CAR-T cell therapies as part of immunotherapy initiatives is crucial. In terms of glioblastoma treatments, specifically where they occur recurrently or are high-grade, patients have benefited from this therapy, which could greatly improve their conditions if expanded through further research or clinical trials. Companies that successfully develop effective immunotherapies can gain a competitive advantage by addressing significant unmet needs in glioma care.
• Advancement of Precision Medicine: Developing molecular profile-based precision medicine approaches creates individualized, gene mutation-specific targeted therapies against molecular abnormalities within gliomas. This development will enhance uptake into personal profiling. With improved genomic sequencing and biomarker discovery, capitalization towards targeted patients becomes more practical, signifying an investment opportunity in frontier scientific research and technology.
• Growth in Advanced Imaging Technologies: Investment in better diagnostic tools based on advanced imaging techniques is essential. Modern imaging modalities such as functional MRI and PET scans provide insights about tumor characteristics and responses to therapy. Enhanced imaging capabilities also improve monitoring and surgical procedures. Hence, there is an attractive opportunity for companies involved in imaging technologies to provide innovative solutions that address the current deficiencies in glioma care.
• Innovations in Drug Delivery Systems: The development of novel drug delivery systems to improve blood-brain barrier penetration and therapeutic efficacy is crucial. Therapeutic agents can be delivered to tumor sites using innovative drug delivery technologies like convection-enhanced delivery and nanotechnology. These advances highlight concerns regarding drug penetration and effectiveness, thus offering immense potential for better treatment outcomes. This presents an avenue for competitive advantage if firms specialize in related developments that are then commercialized within the glioma market.
• Expansion into Emerging Markets: Expanding presence in emerging markets experiencing growing demand for advanced glioma treatments is vital. Markets such as India and China have significant potential due to increased healthcare infrastructure and an ever-rising number of patients. Establishing a presence in these regions may result in new cash flows and address unmet needs. Partnerships with local stakeholders to facilitate entry and growth into established markets should be formed. Additionally, business models tailored to meet specific country requirements can be developed.

Strategic growth opportunities include expanding immunotherapy, advancing precision medicine, investing in advanced imaging technologies, innovating drug delivery systems, and targeting emerging markets. Taking advantage of these opportunities promotes innovation while enhancing patients' well-being and advancing market positions among stakeholders in the glioma treatment industry.

Glioma Treatment Market Driver and Challenges

The market for the treatment of gliomas is shaped by several technological, economic, and regulatory factors that drive growth and present challenges. Navigating the market and developing effective strategies require an understanding of these drivers and challenges. Key drivers include advancements in research and technology, evolving treatment protocols, and increasing demand for personalized medicine, while high costs of development present challenges, including regulatory hurdles and market competition.

The factors responsible for driving the glioma treatment market include:

1. Technological Advancements: Technological advances in genomics, imaging modalities, and drug delivery systems are major factors driving glioma treatment market growth. Innovations such as advanced imaging techniques and precision medicine allow for more accurate diagnosis and targeted treatments. Reports indicate that the blood-brain barrier (BBB) can be bypassed through innovative drug delivery systems, enhancing therapeutic efficacy. These developments improve the choices available to patients, leading to better outcomes.

2. Increased Investment in Research and Development: Increased investment in research and development is essential for advancing glioma treatments. Funding for clinical trials, drug discovery investments, and innovative therapies have driven progress, leading to new treatment options. Such investments from pharmaceutical companies, governmental agencies, or research institutions facilitate the development of cutting-edge therapies, hastening the conversion of scientific discoveries into medical practice at hospitals.

3. Growing Demand for Personalized Medicine: The trend toward personalized medicine is a key driver in the glioma treatment market. By relying on genetic or molecular profiling, there is potential for developing specific targeted treatments against particular tumor characteristics. This approach improves efficacy while managing side effects, aligning with the growing demand for patient-centered care and precision oncology.

4. Rising Prevalence of Gliomas: The rising prevalence of gliomas has led to increased demand for effective remedies, contributing to its growing markets. Incidences may rise due to an aging population and other environmental influences. This increasing demand for treatment drives innovation and investment in new therapies and technologies.

5. Regulatory Support and Incentives: The development of new glioma treatments is encouraged by regulatory support and incentives, such as fast-track approvals and orphan drug funding. Regulatory agencies provide support that aids in the approval and commercialization of innovative drugs, facilitating their entry into the market and bridging gaps within glioma care.

Challenges in the glioma treatment market include:

6. High Costs of Development: The high costs of developing new treatments for gliomas, including research activities, clinical trials, and compliance with regulations, pose a major challenge. These expenses can render small companies less able to bring new drugs to market, potentially impacting pricing models and access for patients.

7. Regulatory Hurdles: Navigating through regulatory requirements to obtain approval for novel glioma treatments can be intricate and time-consuming. Strict clinical trial regulations and safety evaluations make it challenging for any company to enter this market, raising development costs and delaying market entry.

8. Market Competition: With several players vying for a share in the glioma treatment market, it is highly competitive. Pricing strategies and positioning in this sector may be influenced by established pharmaceutical manufacturers as well as newcomers. Product differentiation and demonstrating clinical effectiveness are key factors, particularly when trying to compete favorably.

Drivers such as technological advancements, increased research investment, personalized medicine, rising prevalence rates, and regulatory support influence the glioma treatment market, while high development costs, regulatory hurdles, and intense competition present challenges. Addressing these factors is crucial for advancing glioma treatments, as they lead to success in an evolving marketplace.

List of Glioma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glioma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glioma treatment companies profiled in this report include-

• Thermo Fisher Scientific
• Emcure Pharmaceuticals
• Sigma-Aldrich
• Pfizer
• Taj Pharmaceuticals
• Novartis International
• Teva Pharmaceutical Industries
• GE Healthcare
• Siemens Healthineers
• Philips Healthcare

Glioma Treatment by Segment

The study includes a forecast for the global glioma treatment by type, grade, location, end use, and region.

Glioma Treatment Market by Type [Analysis by Value from 2018 to 2030]:

• Primary Tumors
• Secondary Tumors

Glioma Treatment Market by Grade [Analysis by Value from 2018 to 2030]:

• Low Grade Glioma
• High Grade Glioma
• Recurrent High Grade Glioma

Glioma Treatment Market by Location [Analysis by Value from 2018 to 2030]:

• Supratentorial
• Infratentorial

Glioma Treatment Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Diagnostic Centers
• Medical Research Centers
• Others

Glioma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Glioma Treatment Market

Gliomas are a challenging group of brain tumors that differ in aggressiveness and response to treatment. The development of glioma treatments, including improvements in medical technology, new drug therapies, and changing treatment procedures, have been recent drivers. Several areas have experienced various improvements as clinics and researchers strive to reduce patients' disabilities and fatalities. Currently, there is an increasing emphasis on personalized medicine, improved diagnostic techniques, and advanced treatment modalities in the glioma market. This overview highlights key developments in glioma treatment across the United States, China, Germany, India, and Japan, reflecting global efforts to combat this complex disease.

• United States: In the U.S., there is growing interest in using personalized medicine for glioma therapy as well as targeted approaches. The advent of molecular profiling and genomics has made it possible for drugs targeting specific genetic mutations associated with gliomas to be developed. New immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, are being tested and have shown promising results. Additionally, combination research is ongoing to address some of the limitations associated with traditional treatments, including novel drug delivery systems. Moreover, innovative surgical techniques, including intraoperative imaging technologies and minimally invasive approaches, have reduced both surgical times and patient outcomes.
• China: China has made significant progress in treating glioma by heavily investing in research. Specific institutions within China focus on the molecular characterization of these tumors to develop targeted therapies, among other aspects of precision medicine. Ongoing trials include exploring the effectiveness of new medications like oncolytic virus therapy and targeted radiotherapy. Additionally, breakthroughs in cutting-edge care pathways that allow partnerships between local pharmaceutical companies and biotech startups across borders will facilitate more rapid access to high-performance drugs within China, improving patients' quality of life.
• Germany: Germany has been a leader in combining high-tech imaging techniques with precision medicine for glioma treatment. Techniques involving the use of functional MRI and PET scans help doctors visualize tumors better and plan surgical operations. Moreover, this country is developing and applying novel therapeutic agents such as targeted therapy and immunotherapy. Researchers from various institutions are also exploring modern methods that can enhance patient outcomes when used alongside traditional treatments. Furthermore, its strong regulatory environment, with well-regulated clinical trials, guarantees rigorous testing of new therapies, allowing for quicker incorporation into medical practice.
• India: Recent advances in glioma treatment in India have been based on innovation and resource optimization, allowing advanced treatments to be accessible to many patients through public-private partnerships while ensuring top-notch medical services at major healthcare facilities. They are also investigating low-cost, effective treatment options suitable for diverse communities. The increasing use of radiotherapy and chemotherapy is notable, as ongoing tests aim to examine how well patients respond to various medications or combined care regimens. Enhancing diagnostic facilities and improving infrastructure for treating glioma is essential for providing better care to all patients suffering from these conditions within India.
• Japan: Japan has witnessed a surge in brain tumor treatment developments characterized by an emphasis on novel therapies and precision medicine. The nation is currently investing in the creation of new therapeutic agents, such as gene and targeted therapies, for use in targeted treatment regimens. Japanese institutions are considering the fusion of advanced imaging techniques and surgical procedures to improve outcomes in glioma surgeries. Additionally, Japan has made major contributions to the development of immunotherapies and personalized treatment plans based on individual genetic profiles. Such collaborations, combined with a strong regulatory environment, facilitate the quick application of research discoveries to clinical settings, thereby enhancing glioma treatment options.

Features of the Global Glioma Treatment Market

Market Size Estimates: Glioma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glioma treatment market size by various segments, such as by type, grade, location, end use, and region in terms of value ($B).

Regional Analysis: Glioma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, grades, locations, end uses, and regions for the glioma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glioma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the glioma treatment market by type (primary tumors and secondary tumors), grade (low grade glioma, high grade glioma, and recurrent high grade glioma), location (supratentorial and infratentorial), end use (hospitals & clinics, diagnostic centers, medical research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glioma Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Glioma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Glioma Treatment Market by Type
  • 3.3.1: Primary Tumors
  • 3.3.2: Secondary Tumors
• 3.4: Global Glioma Treatment Market by Grade
  • 3.4.1: Low Grade Glioma
  • 3.4.2: High Grade Glioma
  • 3.4.3: Recurrent High Grade Glioma
• 3.5: Global Glioma Treatment Market by Location
  • 3.5.1: Supratentorial
  • 3.5.2: Infratentorial
• 3.6: Global Glioma Treatment Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Diagnostic Centers
  • 3.6.3: Medical Research Centers
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Glioma Treatment Market by Region
• 4.2: North American Glioma Treatment Market
  • 4.2.1: North American Glioma Treatment Market by Type: Primary Tumors and Secondary Tumors
  • 4.2.2: North American Glioma Treatment Market by End Use: Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, and Others
• 4.3: European Glioma Treatment Market
  • 4.3.1: European Glioma Treatment Market by Type: Primary Tumors and Secondary Tumors
  • 4.3.2: European Glioma Treatment Market by End Use: Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, and Others
• 4.4: APAC Glioma Treatment Market
  • 4.4.1: APAC Glioma Treatment Market by Type: Primary Tumors and Secondary Tumors
  • 4.4.2: APAC Glioma Treatment Market by End Use: Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, and Others
• 4.5: ROW Glioma Treatment Market
  • 4.5.1: ROW Glioma Treatment Market by Type: Primary Tumors and Secondary Tumors
  • 4.5.2: ROW Glioma Treatment Market by End Use: Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Glioma Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Glioma Treatment Market by Grade
  • 6.1.3: Growth Opportunities for the Global Glioma Treatment Market by Location
  • 6.1.4: Growth Opportunities for the Global Glioma Treatment Market by End Use
  • 6.1.5: Growth Opportunities for the Global Glioma Treatment Market by Region
• 6.2: Emerging Trends in the Global Glioma Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Glioma Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glioma Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: Emcure Pharmaceuticals
• 7.3: Sigma-Aldrich
• 7.4: Pfizer
• 7.5: Taj Pharmaceuticals
• 7.6: Novartis International
• 7.7: Teva Pharmaceutical Industries
• 7.8: GE Healthcare
• 7.9: Siemens Healthineers
• 7.10: Philips Healthcare